search
Back to results

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Primary Purpose

Gastrinoma, Glucagonoma, Insulinoma

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
sorafenib tosylate
Sponsored by
National Cancer Institute (NCI)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastrinoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Criteria: Histologically confirmed neuroendocrine tumor: Carcinoid tumor OR islet cell carcinoma/other well-differentiated tumor No anaplastic or high-grade histology Metastatic disease Measurable disease No thyroid carcinoma of any histology, thymoma, or pheochromocytoma/paraganglioma No known brain metastases Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2 Life expectancy: At least 24 weeks Hematopoietic: Absolute neutrophil count >= 1,500/mm3 Platelet count >= 100,000/mm3 No bleeding diathesis Hepatic: Bilirubin =< 2 times upper limit of normal (ULN) Aspartate aminotransferase (AST) =< 3 times ULN (5 times ULN if liver metastases are present) International normalized ratio (INR) normal PTT normal Renal: Creatinine =< 1.5 times ULN Cardiovascular: No poorly controlled hypertension; No symptoms of congestive heart failure; No unstable angina pectoris; No cardiac arrhythmia Gastrointestinal: Able to swallow capsules intact No gastrointestinal tract disease resulting in an inability to take oral medication (e.g., dysphagia) No requirement for IV alimentation No active peptic ulcer disease Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No ongoing or active infection No psychiatric illness or social situation that would preclude study compliance No other invasive malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No other uncontrolled illness At least 4 weeks since prior interferon No more than 1 prior systemic chemotherapy regimen: Chemoembolization is not considered systemic chemotherapy At least 4 weeks since prior chemoembolization At least 3 weeks since prior radiotherapy No prior procedures adversely affecting intestinal absorption At least 4 weeks since prior hepatic artery embolization No other prior systemic therapy No other concurrent investigational treatment No concurrent combination antiretroviral therapy for HIV-positive patients No concurrent enzyme-inducing anticonvulsants (e.g., carbamazepine, phenobarbital, or phenytoin) No concurrent rifampin No concurrent Hypericum perforatum (St. John's wort) Prior or concurrent octreotide for symptomatic treatment allowed No concurrent therapeutic anticoagulation: Concurrent prophylactic anticoagulation (i.e., low dose warfarin) of venous or arterial access devices allowed provided requirements for INR or PTT are met At least 4 weeks since prior major surgery Recovered from all prior therapy

Sites / Locations

  • Mayo Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Group A (patients with carcinoid tumors)

Group B (islet cell and other neuroendocrine tumors)

Arm Description

Patients receive 400 mg oral sorafenib twice daily on days 1-28.

Patients receive 400 mg oral sorafenib twice daily on days 1-28.

Outcomes

Primary Outcome Measures

Confirmed Response Rate
Confirmed response rate was defined using Response Evaluation Criteria In Solid Tumors (RECIST). A confirmed response is defined as a complete response (CR) or partial response (PR) observed on subsequent scans at least 4 weeks apart. Confirmed response rate was estimated by the number of successes divided by the total number of evaluable patients.> > Complete Response (CR) is defined as the disappearance of all target lesions.> Partial Response (PR) is defined as a 30% decrease in sum of longest diameter of target lesions;> > We report the percentage of patients with a confirmed response and a 95% confidence interval estimated by the Duffy and Santner method.

Secondary Outcome Measures

Toxicity
For this secondary endpoint, toxicity is defined as a grade 3 or higher adverse events that is classified as either possibly, probably, or definitely related to study treatment. The assignment of attribution to study treatment and grade (or degree of severity) of the adverse event are classified using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The number of participants reporting a grade 3 or higher toxicity are reported.
Overall Survival
Overall survival (OS) was defined as the time from registration to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method.
Progression Free Survival
Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST) as a 20% increase in the su of longest diameter of target lesions. Progression free survival (PFS) was defined as the time from registration to progression or death of any cause. Participants who were progression free were censored at the date of their most recent disease assessment. The median PFS with 95% CI was estimated using the Kaplan Meier method.
Duration of Response
Duration of response (DOR) was defined as the time from attaining a response (PR or CR) to the date of progression. Participants without progression were censored at the date of their most recent disease assessment. The median DOR was estimated using simple summary statistics.

Full Information

First Posted
August 16, 2005
Last Updated
November 14, 2014
Sponsor
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00131911
Brief Title
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Official Title
A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
June 2014
Overall Recruitment Status
Completed
Study Start Date
June 2005 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
April 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Cancer Institute (NCI)

4. Oversight

5. Study Description

Brief Summary
This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Detailed Description
PRIMARY OBJECTIVES: I. To determine the objective tumor response rate of BAY 43-9006 (sorafenib tosylate) in patients with advanced neuroendocrine tumors. SECONDARY OBJECTIVES: I. Adverse event rate(s). II. Progression free survival and time to progression. III. Improvement in circulating hormone levels. IV. Overall survival. OUTLINE: This is a multicenter study. Patients are grouped into 2 separate analysis Groups according to tumor type (Group A: Carcinoid; Group B: Islet cell/other well-differentiated tumor). Each Group was independently evaluated for all study endpoints. Patients receive oral sorafenib tosylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 2 years from study entry.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Neuroendocrine Tumor, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma, WDHA Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
93 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A (patients with carcinoid tumors)
Arm Type
Experimental
Arm Description
Patients receive 400 mg oral sorafenib twice daily on days 1-28.
Arm Title
Group B (islet cell and other neuroendocrine tumors)
Arm Type
Experimental
Arm Description
Patients receive 400 mg oral sorafenib twice daily on days 1-28.
Intervention Type
Drug
Intervention Name(s)
sorafenib tosylate
Other Intervention Name(s)
BAY 43-9006, BAY 43-9006 Tosylate Salt, BAY 54-9085, Nexavar, SFN
Intervention Description
400 mg given orally
Primary Outcome Measure Information:
Title
Confirmed Response Rate
Description
Confirmed response rate was defined using Response Evaluation Criteria In Solid Tumors (RECIST). A confirmed response is defined as a complete response (CR) or partial response (PR) observed on subsequent scans at least 4 weeks apart. Confirmed response rate was estimated by the number of successes divided by the total number of evaluable patients.> > Complete Response (CR) is defined as the disappearance of all target lesions.> Partial Response (PR) is defined as a 30% decrease in sum of longest diameter of target lesions;> > We report the percentage of patients with a confirmed response and a 95% confidence interval estimated by the Duffy and Santner method.
Time Frame
Duration of Treatment (Up to 2 years)
Secondary Outcome Measure Information:
Title
Toxicity
Description
For this secondary endpoint, toxicity is defined as a grade 3 or higher adverse events that is classified as either possibly, probably, or definitely related to study treatment. The assignment of attribution to study treatment and grade (or degree of severity) of the adverse event are classified using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. The number of participants reporting a grade 3 or higher toxicity are reported.
Time Frame
Up to 2 years
Title
Overall Survival
Description
Overall survival (OS) was defined as the time from registration to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method.
Time Frame
From registration to death (up to 2 years)
Title
Progression Free Survival
Description
Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST) as a 20% increase in the su of longest diameter of target lesions. Progression free survival (PFS) was defined as the time from registration to progression or death of any cause. Participants who were progression free were censored at the date of their most recent disease assessment. The median PFS with 95% CI was estimated using the Kaplan Meier method.
Time Frame
Time from registration to progression or death (up to 2 years)
Title
Duration of Response
Description
Duration of response (DOR) was defined as the time from attaining a response (PR or CR) to the date of progression. Participants without progression were censored at the date of their most recent disease assessment. The median DOR was estimated using simple summary statistics.
Time Frame
Time from response to progression (up to 2 years)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Criteria: Histologically confirmed neuroendocrine tumor: Carcinoid tumor OR islet cell carcinoma/other well-differentiated tumor No anaplastic or high-grade histology Metastatic disease Measurable disease No thyroid carcinoma of any histology, thymoma, or pheochromocytoma/paraganglioma No known brain metastases Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2 Life expectancy: At least 24 weeks Hematopoietic: Absolute neutrophil count >= 1,500/mm3 Platelet count >= 100,000/mm3 No bleeding diathesis Hepatic: Bilirubin =< 2 times upper limit of normal (ULN) Aspartate aminotransferase (AST) =< 3 times ULN (5 times ULN if liver metastases are present) International normalized ratio (INR) normal PTT normal Renal: Creatinine =< 1.5 times ULN Cardiovascular: No poorly controlled hypertension; No symptoms of congestive heart failure; No unstable angina pectoris; No cardiac arrhythmia Gastrointestinal: Able to swallow capsules intact No gastrointestinal tract disease resulting in an inability to take oral medication (e.g., dysphagia) No requirement for IV alimentation No active peptic ulcer disease Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No ongoing or active infection No psychiatric illness or social situation that would preclude study compliance No other invasive malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix No other uncontrolled illness At least 4 weeks since prior interferon No more than 1 prior systemic chemotherapy regimen: Chemoembolization is not considered systemic chemotherapy At least 4 weeks since prior chemoembolization At least 3 weeks since prior radiotherapy No prior procedures adversely affecting intestinal absorption At least 4 weeks since prior hepatic artery embolization No other prior systemic therapy No other concurrent investigational treatment No concurrent combination antiretroviral therapy for HIV-positive patients No concurrent enzyme-inducing anticonvulsants (e.g., carbamazepine, phenobarbital, or phenytoin) No concurrent rifampin No concurrent Hypericum perforatum (St. John's wort) Prior or concurrent octreotide for symptomatic treatment allowed No concurrent therapeutic anticoagulation: Concurrent prophylactic anticoagulation (i.e., low dose warfarin) of venous or arterial access devices allowed provided requirements for INR or PTT are met At least 4 weeks since prior major surgery Recovered from all prior therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timothy Hobday
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

We'll reach out to this number within 24 hrs